Who makes local anesthesics, CLIFE2?

local anesthesics, CLIFE2 is developed by Hospital de Viladecans.

What development phase is local anesthesics, CLIFE2 in?

local anesthesics, CLIFE2 is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

local anesthesics, CLIFE2

Hospital de Viladecans · FDA-approved active Small molecule Quality 2/100

CLIFE2 is a marketed local anesthetic developed by Hospital de Viladecans, currently holding a position in the anesthetics market. A key strength of CLIFE2 is its patent protection, which extends until 2028, providing a period of exclusivity for the key composition. The primary risk facing CLIFE2 is the potential increase in competition once the key patent expires in 2028.

At a glance

Generic name	local anesthesics, CLIFE2
Also known as	lidocaine, CLEFE2 topical gel
Sponsor	Hospital de Viladecans
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of CLIFE1 Gel in Benign Anorectal Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

local anesthesics, CLIFE2 CI brief — competitive landscape report
local anesthesics, CLIFE2 updates RSS · CI watch RSS
Hospital de Viladecans portfolio CI